在PARP抑制和化疗的治疗压力下,BRCA2逆转突变的融合进化
Charlotte S Walmsley1,2, Philip Jonsson3, Michael L Cheng3
1Beth Israel Deaconess Medical Center, Boston, MA, USA.
NPJ precision oncology
|February 14, 2024
概括
在前列腺癌中,BRCA2逆转突变可能导致对Poly (ADP-ribose) 聚合酶 (PARP) 抑制剂的抗性. 这项研究在一个患者中发现了多个BRCA2逆转突变,突出了克隆选择和通过无细胞DNA监测耐药性的局限性.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 基因组学就是基因组学.
背景情况:
- 在BRCA相关癌症中对Poly (ADP-ribose) 聚合酶 (PARP) 抑制剂的获得耐药性通常是由BRCA基因逆转突变驱动的.
- 转移性割抵抗性前列腺癌 (mCRPC) 具有生殖系BRCA2突变是研究PARP抑制剂耐药性的重要背景.
研究的目的:
- 为了研究一个患有mCRPC和生殖系BRCA2突变的患者对PARP抑制的获得性耐药性的基因组景观.
- 在治疗压力下的BRCA2逆转突变的异质性和克隆选择的特征.
主要方法:
- 使用无细胞DNA (cfDNA) 和组织样本进行广泛的基因组调查.
- 在多个时间点进行分析:基线,后进展和死后.
- 识别和表征BRCA2逆转突变.
主要成果:
- 在患者的十个不同的瘤部位中,发现了十个独特的BRCA2逆转突变.
- 十分之九的瘤至少存在一种逆转突变,这表明了强烈的克隆选择.
- 在瘤部位观察到可变的cfDNA分泌,这对抗性监测构成了挑战.
结论:
- PARP抑制施加了显著的选择性压力,有利于mCRPC中BRCA2逆转突变的出现.
- 这些突变的空间和时间异质性使抗性检测复杂化.
- 目前的cfDNA监测策略可能在捕获PARPi抗性机制的全谱方面存在局限性.
更多相关视频
09:22Functional Assessment of BRCA1 variants using CRISPR-Mediated Base Editors
Published on: February 28, 2021
5.5K
08:15gDNA Enrichment by a Transposase-based Technology for NGS Analysis of the Whole Sequence of BRCA1, BRCA2, and 9 Genes Involved in DNA Damage Repair
Published on: October 6, 2014
12.3K
相关概念视频
Restarting Stalled Replication Forks
5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Gene Conversion
9.8K
Other than maintaining genome stability via DNA repair, homologous recombination plays an important role in diversifying the genome. In fact, the recombination of sequences forms the molecular basis of genomic evolution. Random and non-random permutations of genomic sequences create a library of new amalgamated sequences. These newly formed genomes can determine the fitness and survival of cells. In bacteria, homologous and non-homologous types of recombination lead to the evolution of new...
9.8K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Conservative Site-specific Recombination and Phase Variation
6.0K
Because the DNA segments are cut and reorganized in a direction-specific manner, site-specific recombination has emerged as an efficient genetic engineering technique. Flippase and Cyclization recombinases or Flp and Cre, respectively, are two members of the tyrosine recombinase family derived from bacteriophages, that are used to mediate site-specific DNA insertions, deletions, and targeted expression of proteins in mammalian cell lines.
The recognition sites for Cre recombinase called LoxP...
The recognition sites for Cre recombinase called LoxP...
6.0K
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
